Glucosidase, prepro-a- [199-arginine,223-histidine] (human)

Glucosidase, prepro-a- [199-arginine,223-histidine] (human) Suppliers list
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Myozyme/Alglucosidase Alfa (DHC80029)
CAS:420784-05-0
Purity:PAGE:>95% Package:100ug;1mg
Company Name: Atagenix Laboratories  
Tel: 027-87008169 17762441161
Email: info@atagenix.com
Products Intro: Product Name:Research Grade Myozyme/Alglucosidase Alfa
CAS:420784-05-0
Purity:>95% Package:100ug
Glucosidase, prepro-a- [199-arginine,223-histidine] (human) Basic information
Product Name:Glucosidase, prepro-a- [199-arginine,223-histidine] (human)
Synonyms:Glucosidase, prepro-a- [199-arginine,223-histidine] (human);Research Grade Myozyme/Alglucosidase Alfa (DHC80029);Research Grade Myozyme/Alglucosidase Alfa
CAS:420784-05-0
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Glucosidase, prepro-a- [199-arginine,223-histidine] (human)
 Structure
Glucosidase, prepro-a- [199-arginine,223-histidine] (human) Chemical Properties
Safety Information
MSDS Information
Glucosidase, prepro-a- [199-arginine,223-histidine] (human) Usage And Synthesis
DescriptionPompe disease is a lysosomal storage disorder that is characterized by a deficiency in the acid alpha-glucosidase enzyme that is responsible for the breakdown of glycogen to glucose. The lack of degradation results in the accumulation of glycogen in lysosomes, predominantly affecting cardiac and skeletal muscles. In cases of complete enzyme deficit, such as observed in the infantile manifestation, cardiomyopathy, and skeletal muscle myopathy occur with fatal consequences. As with other lysosomal storage disorders, enzyme replacement therapy (ERT) is the patient’s only hope. Alglucosidase alfa has been developed and launched as the ERT for Pompe disease. As a recombinant human enzyme, it is produced by transfected CHO cells as a 110-kDa precursor that targets lysosomes via the mannose-6-phosphate (M6P) receptor. Following endocytosis, the enzyme is transformed to its mature 76-kDa form that restores glycogen processing and reverses accumulation. The dosing regimen of alglucosidase alfa is 20 mg/kg infused over a period of 4 h every two weeks. The pharmacokinetic properties are dose-proportional between 20 and 40mg/kg.
OriginatorDuke University (US)
Brand nameMyozyme
Glucosidase, prepro-a- [199-arginine,223-histidine] (human) Preparation Products And Raw materials
Tag:Glucosidase, prepro-a- [199-arginine,223-histidine] (human) (420784-05-0) Related Product Information